Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karen J Froning

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal for Immunotherapy of Cancer|March 9, 2022
Generalizable design parameters for soluble T cell receptor-based T cell engagersKaren J Froning, Arlene Sereno, Flora Huang, et al.
Mabs|July 4, 2024
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapyAmelia C McCue, Stephen J Demarest, Karen J Froning, et al.
Structure (London, England : 1993)|March 22, 2016
Computationally Designed Bispecific Antibodies using Negative State RepertoiresAndrew Leaver-Fay, Karen J Froning, Shane Atwell, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|March 9, 2022
Generalizable design parameters for soluble T cell receptor-based T cell engagersKaren J Froning, Arlene Sereno, Flora Huang, et al.
Mabs|July 4, 2024
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapyAmelia C McCue, Stephen J Demarest, Karen J Froning, et al.
Structure (London, England : 1993)|March 22, 2016
Computationally Designed Bispecific Antibodies using Negative State RepertoiresAndrew Leaver-Fay, Karen J Froning, Shane Atwell, et al.
The Journal of Biological Chemistry|October 28, 2004
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinaseShane Atwell, Jason M Adams, John Badger, et al.
Molecular Cancer Therapeutics|November 26, 2009
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivoSean G Buchanan, Jorg Hendle, Patrick S Lee, et al.
Pageof 1